ELL2

Across TCGA pan-cancer cohorts, ELL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELL2 data layer compared with 18 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ELL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ELL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where ELL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	1.000	0.770	.011	14	view →
PDAC	DFS	Median	All	0.479	0.960	.013	8	view →
UCEC	OS	Median	III,IV	1.000	0.366	.034	4	view →
LSCC	OS	Median	All	1.000	0.919	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ELL2–LUAD (OS)

Open the LUAD breakdown →